James Evan Dodd

Dr. James Evan Dodd

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2026 in Journal of Vascular Surgery
Verified
Journal Article
Open access
BMBibombe Patrice Mwipatayi
Bibombe Patrice Mwipatayi
JDJames Evan Dodd
James Evan Dodd
ABAmirul H. Ahmad Bazlee
Amirul H. Ahmad Bazlee
GJGlynis Jones
Glynis Jones
HVHence J.M. Verhagen
Hence J.M. Verhagen
MSMarkus P. Schlaich
Markus P. Schlaich
Lipoprotein(a) [Lp(a)] is an atherogenic and prothrombotic lipoprotein with a well-established role in cardiovascular disease. However, its association with peripheral artery disease (PAD) prevalence and limb-related outcomes following lower-extremity revascularization remains incompletely defined. We conducted a systematic review and meta-analysis to evaluate the relationship between elevated Lp(a), PAD prevalence, and post-revascularization limb outcomes. A systematic review was performed in accordance with PRISMA guidelines. MEDLINE, Embase, CINAHL, and Web of Science were searched from January 1990 through August 2024 to identify observational studies reporting associations between Lp(a) levels and PAD prevalence and/or outcomes following lower-extremity revascularization. Risk of bias was assessed using ROBINS-E and ROB-2, and certainty of evidence was graded using the GRADE framework. Pooled odds ratios (ORs) and mean differences were estimated using random-effects models. Between-study heterogeneity was quantified using the I2 statistic and prespecified sensitivity and subgroup analyses were performed. Ten observational studies comprising 5,794 participants met inclusion criteria. Elevated Lp(a) was associated with a significantly higher prevalence of PAD (pooled OR, 1.81; 95% confidence interval [CI], 1.37-2.39; P < .001), with low heterogeneity (I2 = 26%). This association remained consistent in prospective cohort studies (OR, 1.60; 95% CI, 1.24-2.07; I2 = 0%). Patients with PAD also had higher circulating Lp(a) concentrations than non-PAD control participants (mean difference, 21.8 mg/dL; 95% CI, -5.5 to 49.1), although heterogeneity was substantial (I2 = 85%). Among patients undergoing lower-extremity revascularization, only two observational cohort studies contributed to pooled limb-outcome analyses. Within this limited evidence base, elevated Lp(a) was strongly associated with adverse limb outcomes, including repeat target-lesion revascularization (TLR) (OR, 3.22; 95% CI, 2.36-4.40), major adverse limb events (OR, 5.09; 95% CI, 3.89-6.67), and major amputation (OR, 2.62; 95% CI, 1.36-5.03), with no detectable heterogeneity across these endpoints (I2 = 0%). Several included studies reported estimates adjusted for established vascular risk factors, including diabetes mellitus, smoking, hypertension, and lipid-lowering therapy; however, harmonized adjusted estimates were not available for all pooled analyses. Elevated lipoprotein(a) is consistently associated with increased PAD prevalence and adverse limb-related outcomes following lower-extremity revascularization. These findings better define Lp(a) as a marker of limb-related risk and postprocedural prognosis in PAD. However, the current evidence remains insufficient to conclude that Lp(a)-directed treatment improves PAD-specific outcomes.

Verified
Journal Article
Open access
PDF file
ISIrina Shevchenko
Irina Shevchenko
BLBernardette Jingfei Lee
Bernardette Jingfei Lee
DDDavina Daudu
Davina Daudu
JDJames Evan Dodd
James Evan Dodd
JWJacqueline Wong
Jacqueline Wong
BMBibombe Patrice Mwipatayi
Bibombe Patrice Mwipatayi
Background: Femoral arteriotomy closure after peripheral angiography and intervention is commonly achieved using vascular closure devices (VCDs) or compression-based strategies; however, comparative randomised data in contemporary peripheral endovascular practice remain limited. Methods: In this prospective randomised trial, adults undergoing femoral-access diagnostic angiography or peripheral endovascular intervention were assigned in a 1:1 ratio to haemostasis with the FemoStop™ II Gold pneumatic compression system or a contemporary VCD strategy. The primary endpoint was a composite of major or minor groin-site complications immediately after sheath removal. Secondary endpoints included composite complications at recovery, discharge, and 30 days, with separate analyses of major and minor complications. Patient-reported pain was assessed using the Verbal Numerical Rating Scale (VNRS). Efficacy and safety analyses were performed according to the intention-to-treat and as-treated principles, respectively. Risk ratios were estimated using modified Poisson regression with robust variance, with prespecified adjustment for sex, systolic blood pressure before sheath removal, and sheath size. Results: A total of 130 participants underwent randomisation, including 66 assigned to FemoStop™ II Gold and 64 assigned to VCDs. The primary composite endpoint occurred in 23/66 participants (34.9%) in the FemoStop™ II Gold group and 16/64 (25.0%) in the VCD group (absolute difference, 9.9 percentage points; 95% confidence interval [CI], −6.1 to 25.7; p = 0.25), with the numerical difference driven predominantly by minor-only events (28.8% versus 15.6%; p = 0.09). At 30 days, the composite endpoint occurred in 17/66 participants (25.8%) and 12/64 participants (18.8%), respectively (absolute difference, 7.0 percentage points; 95% CI, −13.3 to 26.4; p = 0.40). Serious access-site events remained infrequent both immediately post-procedure (6.1% versus 9.4%; p = 0.53) and at 30 days (6.1% versus 4.7%; p = 0.72). The adjusted risk ratios were 1.28 (95% CI, 0.74 to 2.21) for the primary composite endpoint and 1.23 (95% CI, 0.63 to 2.40) for the 30-day composite endpoint. Ordinal VNRS pain distributions did not differ significantly at any timepoint, although “any pain” immediately post-procedure was less frequent with FemoStop™ II Gold (22.7% versus 40.6%; unadjusted risk ratio, 0.56; 95% CI, 0.33 to 0.93); this association was attenuated after adjustment (adjusted risk ratio, 0.63; 95% CI, 0.38 to 1.03). Prespecified interaction testing suggested that the effect of treatment on composite complications varied according to sheath size both immediately post-procedure and at 30 days (p < 0.001 for both interactions). Conclusions: In patients undergoing femoral-access diagnostic angiography or peripheral endovascular intervention, haemostasis with FemoStop™ II Gold resulted in 30-day groin-site complication rates that did not differ significantly from those observed with contemporary VCD strategies. Serious access-site events remained infrequent in both groups, and the apparent early reduction in patient-reported pain with FemoStop™ II Gold was not definitive after adjustment. Larger, adequately powered multicentre studies are warranted to clarify sheath size-dependent effects and uncommon clinically consequential vascular events.

Verified
Journal Article
Open access
PDF file
BMBibombe Patrice Mwipatayi
Bibombe Patrice Mwipatayi
BLBernardette Jingfei Lee
Bernardette Jingfei Lee
DDDavina Daudu
Davina Daudu
JDJames Evan Dodd
James Evan Dodd
MMMariah Theresa Mwipatayi
Mariah Theresa Mwipatayi
MSMarkus P SCHLAICH
Markus P SCHLAICH
Background: Restenosis and occlusion remain important after aortoiliac stenting, and device choice does not fully explain late patency loss. Lipoprotein(a) [Lp(a)] is implicated in atherosclerotic progression and residual vascular risk. Objective: To determine whether baseline Lp(a) is associated with long-term restenosis or occlusion after aortoiliac stenting. Methods: This post hoc biomarker analysis of COBEST included 125 patients and 168 treated iliac arteries randomised to the Advanta V12 covered stent (Atrium Medical Corporation, Hudson, NH, USA) or bare-metal stents for symptomatic aortoiliac occlusive disease. The primary outcome was loss of primary patency, defined as restenosis or occlusion during 5-year follow-up. Cox proportional hazards modelling and cumulative failure curves were the main analyses. Results: In the Lp(a)-adjusted Cox model, covered stent use was associated with a lower hazard of restenosis or occlusion (HR, 0.55; 95% CI, 0.31–0.97; p = 0.039), whereas each 1 mg/dL higher Lp(a) concentration was associated with a higher hazard (HR, 1.08; 95% CI, 1.06–1.10; p < 0.001; equivalent to HR, 2.16; 95% CI, 1.79–2.59 per 10 mg/dL increase). In the biomarker-adjusted model, each 1 mg/dL higher Lp(a) concentration (HR, 1.05; 95% CI, 1.02–1.08; p < 0.001; HR, 1.63; 95% CI, 1.22–2.16 per 10 mg/dL increase) and each 1 mmol/L higher triglyceride concentration (HR, 1.89; 95% CI, 1.34–2.68; p < 0.001) remained associated with restenosis or occlusion. Conclusions: Elevated Lp(a) and, to a lesser extent, triglycerides were independently associated with long-term aortoiliac stent failure after adjustment for stent type.

30 October 2026 in Journal of Endovascular Therapy
Verified
Journal Article
Open access
JDJames Evan Dodd
James Evan Dodd
MBMarianne Brodmann
Marianne Brodmann
JWJohn Chaw Chian Wang
John Chaw Chian Wang
GNGiovanni Nano
Giovanni Nano
TZThomas Zeller
Thomas Zeller
BMBibombe Patrice Mwipatayi
Bibombe Patrice Mwipatayi
Background: Chronic limb-threatening ischaemia (CLTI) carries a high risk of death, limb loss, and impaired functional recovery despite revascularisation. Drug-coated balloons may reduce restenosis and repeat intervention after infrainguinal endovascular therapy, but long-term safety and effectiveness data in patients with CLTI remain limited. Methods: We performed a prespecified subgroup analysis of BIOLUX P-III, a prospective international post-market all-comers registry evaluating the Passeo-18 Lux paclitaxel-coated balloon for infrainguinal peripheral artery disease. Outcomes were compared between patients with and without CLTI through 60 months. Endpoints included freedom from major adverse events, clinically driven target-lesion revascularisation, major target-limb amputation, amputation-free survival and all-cause mortality. Time-to-event outcomes were analysed using Kaplan-Meier methods. Because follow-up completeness declined substantially by 60 months, late estimates were interpreted in the context of censoring, attrition and competing mortality. Results: Among 877 treated patients, 328 (37.4%) had CLTI. Technical success exceeded 98% in both groups. Patients with CLTI had greater baseline comorbidity, more advanced limb threat and more frequent below-the-knee disease. At 60 months, freedom from clinically driven target-lesion revascularisation was 85.3% in patients with CLTI and 78.3% in those without CLTI ( P = .59), and freedom from major adverse events was similar (76.5% vs 74.3%; P = .13). In contrast, 5-year survival was substantially lower in patients with CLTI (47.9% vs 76.7%; P < .001). Freedom from major target-limb amputation was lower (93.3% vs 99.3%; P < .001), and amputation-free survival was reduced (47.1% vs 75.7%; P < .001). Patients with CLTI received a lower cumulative paclitaxel dose despite higher mortality. Conclusions: Passeo-18 Lux treatment was associated with preserved lesion-level durability through 5 years, but CLTI identified a high-risk prognostic phenotype with poor survival and limb outcomes. These findings suggest that long-term outcomes in CLTI are influenced by systemic comorbidity, early limb vulnerability, competing mortality and wound-related factors beyond lesion-level device performance alone. Clinical Impact: This study provides clinically relevant insights into the long-term outcomes of patients with chronic limb-threatening ischaemia (CLTI) undergoing endovascular revascularisation with drug-coated balloons. Despite high procedural success, patients with CLTI experience substantially greater long-term mortality and adverse limb outcomes than those with intermittent claudication. These findings highlight the importance of recognising CLTI as a high-risk clinical phenotype requiring comprehensive cardiovascular risk reduction, multidisciplinary management, and structured postprocedural surveillance. The study’s principal contribution is its evaluation of five-year outcomes in a real-world, all-comers population, providing valuable evidence to inform patient counselling, individualised treatment strategies, and long-term clinical decision-making.

13 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BMBibombe Patrice Mwipatayi
Bibombe Patrice Mwipatayi
JDJames Evan Dodd
James Evan Dodd
JHJoseph Hanna
Joseph Hanna
YGYann Gouëffic
Yann Gouëffic
MBMarianne Brodmann
Marianne Brodmann
KDKoen Deloose
Koen Deloose
Background: The BIO REACT study is designed to investigate the incremental value of Extravascular UltraSound (EVUS) added to conventional angiography, compared to conventional angiography only for the identification of Flow-Limiting Dissections (FLD) and to evaluate the safety and efficacy of the REsponse Adapted Combination Therapy (REACT) for the treatment of femoropopliteal lesions. Methods: The primary endpoints were the specificity and sensitivity of EVUS added to angiography for the detection of FLD. Secondary endpoints were primary patency of the REACT therapy within 12 months, fCD-TLR, freedom from MAE, major target limb amputations (mTLA) and survival rates within 24 months. Results: A total of 150 patients were included. EVUS added to angiography had an overall sensitivity of 29% and specificity of 93% for the detection of FLD. There was no PSVR cut-off offering a clinically acceptable trade-off between meaningful sensitivity and specificity values for the detection of FLD. At 12 months, treatment with the REACT resulted in primary patency and fCD-TLR of 81.6% and 94.3%, respectively. In addition, freedom from MAE was 94.3% at 12 months. At 24 months, the survival rate was 94.0%. No mTLA was reported up to the 24-month follow-up. Conclusions: The addition of DUS to angiography showed limited value for detecting FLD in femoropopliteal artery disease.